Patizra

Patizra

ranibizumab

Manufacturer:

Novartis Indonesia
Concise Prescribing Info
Contents
Ranibizumab
Indications/Uses
Neovascular (wet) age-related macular degeneration (AMD). Visual impairment due to diabetic macular edema (DME), macular edema secondary to retinal vein occlusion (RVO) & choroidal neovascularisation (CNV) secondary to pathologic myopia (PM).
Dosage/Direction for Use
0.5 mg (0.05 mL) as a single intravitreal inj. Interval between 2 doses should not be <1 mth. Wet AMD, visual impairment due to DME & macular edema secondary to RVO Treatment is given mthly & continued until visual acuity is stable for 3 consecutive mthly assessments. Visual impairment due to CNV secondary to PM Initiate w/ a single inj. Monitor for signs of disease activity to assess if further treatment is needed.
Contraindications
Hypersensitivity. Patients w/ active or suspected ocular or periocular infections & active intraocular inflammation.
Special Precautions
Proper aseptic inj techniques must be used. Monitor IOP & optic nerve head perfusion. Arterial thromboembolic events. Immunogenecity. May impair ability to drive or operate machines. Pregnancy & lactation. Childn & adolescents <18 yr.
Adverse Reactions
Nasopharyngitis, upper resp tract infection, influenza, UTI (DME patient only). Anaemia. Anxiety. Headache, dizziness, stroke. Eye disorders. Cough. Nausea, constipation. Allergic reactions (rash, urticaria, pruritus, erythema). Arthralgia, back pain, arthritis. Increased IOP. HTN/elevated BP.
MIMS Class
Other Eye Preparations
ATC Classification
S01LA04 - ranibizumab ; Belongs to the class antineovasculatisation agents. Used in the management of neovascular macular degeneration.
Presentation/Packing
Form
Patizra soln for inj 10 mg/mL
Packing/Price
(vial) 0.23 mL x 1's (Rp4,785,000/boks)
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in